Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.8207
+0.01922.40%
Post-market: 0.83960.0189+2.30%17:25 EDT
Volume:617.94K
Turnover:510.68K
Market Cap:15.90M
PE:-1.06
High:0.8544
Open:0.8180
Low:0.8000
Close:0.8015
52wk High:3.78
52wk Low:0.7500
Shares:19.38M
Float Shares:18.13M
Volume Ratio:0.99
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-28.35
PE(LYR):-0.68

Loading ...

Dare Bioscience Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Daré Bioscience to Host Quarterly Results Conference Call and Webcast

Reuters
·
Aug 06

DarÉ Bioscience Expands Access Options for Dare to Play™ and Specialized Menopause Care Through Strategic Collaboration with Mymenopauserx

THOMSON REUTERS
·
Jul 28

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

GlobeNewswire
·
Jul 28

Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?

Simply Wall St.
·
Jul 21

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

GlobeNewswire
·
Jul 20

Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors

TIPRANKS
·
Jul 18

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

GlobeNewswire
·
Jul 09

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

GlobeNewswire
·
Jul 01

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Jun 25

Daré Bioscience CEO speaks at BIO International Convention 2026

Reuters
·
Jun 18

Daré Bioscience shareholders approve 1.5 million-share increase to 2022 stock incentive plan at annual meeting

Reuters
·
Jun 13

DarÉ Bioscience Announces the Upcoming Launch of Flora Sync Lf5™ Vaginal Probiotic Capsules

THOMSON REUTERS
·
Jun 04

Daré Bioscience wins $1 million NIH grant tranche for DARE-HPV program

Reuters
·
May 26

Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dow Jones
·
May 26

BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv

Reuters
·
May 18

Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection

Reuters
·
May 18

DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Dare-Hpv Development Supported by $10 Mln Arpa-H Contract; Topline Data Expected in 2027

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Phase 2 Study to Enroll About 100 Women Over up to 21 Days

THOMSON REUTERS
·
May 18